MedTrace Logo

Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma

NCT02645981 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 668

Last updated 2020-01-09

No results posted yet for this study

Summary

Donafenib versus sorafenib for advanced hepatocellular cancer.

Conditions

Interventions

DRUG

Donafenib

Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects

DRUG

Sorafenib

Control

Sponsors & Collaborators

  • Tigermed Consulting Co., Ltd

    collaborator INDUSTRY

  • Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Shukui Qin, MD · The PLA 81 Hospital

  • Feng Bi, MD · West China Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2019-11-27
Completion
2019-12-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02645981 on ClinicalTrials.gov